Form 4: Catalyst Pharma CFO's Routine Stock Vesting and Tax Sale

Catalyst Pharmaceuticals' EVP & CFO, Michael Kalb, acquired shares from restricted stock unit vesting and disposed of a portion for tax obligations.

Summary

• Michael Wayne Kalb, Executive Vice President & CFO of Catalyst Pharmaceuticals, Inc. (CPRX), reported changes in his beneficial ownership.
• On January 5, 2026, Kalb acquired 7,139 shares of common stock through the vesting of restricted stock units (RSUs).
• Concurrently, 2,080 shares were disposed of to satisfy applicable withholding taxes related to the RSU vesting.
• Following these transactions, Kalb directly beneficially owns 13,665 shares of common stock.
• He also beneficially owns 632,903 derivative securities in the form of Restricted Stock Units.
• The RSUs vest in equal tranches, 1/5th on January 1, 2025, 2026, 2027, 2028, and 2029, with the second tranche delivered on January 5, 2026.

Sentiment

Score: 6

Explanation: The filing reports a routine, pre-scheduled RSU vesting event for an executive, which is a neutral to slightly positive indicator as it represents the realization of long-term compensation. The associated tax withholding is a standard practice and does not reflect a discretionary sale.

Positives

• The vesting of 7,139 restricted stock units indicates the realization of long-term incentive compensation for the Executive Vice President & CFO.
• The transaction reflects a pre-scheduled compensation event, aligning executive incentives with long-term company performance.

Negatives

• A portion of the vested shares (2,080) was withheld by the Registrant to cover tax liabilities, which is a standard practice and not a discretionary sale by the executive.

Stakeholder Impact

• Shareholders: The transaction reflects the ongoing compensation structure for executive management, aligning their interests with long-term company performance through equity incentives.
• Employees: Demonstrates the company's executive compensation practices, which may influence broader employee incentive programs.

Next Steps

• Future tranches of Restricted Stock Units are scheduled to vest on January 1, 2027, January 1, 2028, and January 1, 2029.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Transaction, Restricted Stock Units, RSU Vesting, Executive Compensation, Michael Kalb, CFO